BOLT BIOTHERAPEUTICS INC (BOLT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.82-1.04%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Operating income improves toward break-even: metric not reported.
Bolt is cutting costs to improve its losses. Operating loss fell from $9.2M to $7.6M. The company is working on new cancer drugs. If it succeeds, sales could grow again.
Bolt keeps losing money with no clear path to profit. Sales are expected to fall 34%. The company faces tough competition and high risks.
The market expects about 34% revenue decline and continued losses. Our fair value is $38.38, reflecting these challenges. We see limited upside until profits improve.
Breaks if: Free cash flow yield remains below negative 6% next year
Breaks if: Operating loss worsens beyond negative $7.6M next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as the company is loss-making but shows some operational improvements.
The market seems to have priced in a low expectations gap, indicating that BOLT is viewed as relatively cheap compared to its peers. However, the valuation reflects ongoing concerns about its ability to generate positive earnings.
Management is focused on improving operating income, with some progress noted in recent quarters. However, the company remains at risk of missing earnings expectations, particularly given its smaller size and the high miss rate in its industry.
The future performance of BOLT depends on several factors, including guidance updates from management and the performance of key sector peers. Additionally, broader economic indicators, like the jobs report, could impact investor sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Bolt aims to improve its operating income, which has been negative in recent quarters.
Stated in 4 of last 4 quarters. Operating income improved from negative $9,210,000 in 2025-Q2 to negative $7,601,000 in 2026-Q1, showing some progress. However, the income remains negative, indicating ongoing challenges.
“Operating income was negative at $7,601,000.”
“Operating income was negative at $7,085,000.”
“Operating income was negative at $7,703,000.”
“Operating income was negative at $9,210,000.”
Breaks if: Revenue decline exceeds 34% next year
Over the next 1 to 3 years, BOLT's trajectory will largely depend on its ability to stabilize earnings and navigate sector dynamics. Not investment advice.